SP-420

Phase 2Small molecule

SSideris Pharmaceuticals

SP-420 is one of 98 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromesActive, not recruiting

Beta-ThalassemiaActive, not recruiting

ThalassemiaActive, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Beta-ThalassemiaPhase 2

Active, not recruiting

ThalassemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

207 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Reblozyl

Bristol-Myers Squibb

Phase 3

15 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

8 3

Thalomid

Bristol-Myers Squibb

Phase 3

2 4

Promacta

GSK

Phase 3

2 5

Fludara

Sanofi

Phase 3

2 6

Rydapt

Novartis

Phase 3

1 7

Xospata

Astellas

Phase 3

1 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

4 9

Zarnestra

KKura Oncology, Inc.

Phase 3

4 10

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Myelodysplastic Syndromes

NCT05693909

Clinical

Trials by Indication[1]

Transfusional Iron Overload1 trial

Safety of SP-420 in the Treatment of Transfusional Iron Overload

Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04741542·2 enrolled

Thalassemia1 trial

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Terminated·SSideris Pharmaceuticals·Phase 1·NCT02274233·24 enrolled

Myelodysplastic Syndromes1 trial

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

Recruiting·PPharmacosmos A/S·Phase 2·NCT05693909·90 enrolled

Beta-Thalassemia1 trial

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Withdrawn·AAbfero Pharmaceuticals, Inc·Phase 2·NCT03801889

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SP-420. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SP-420 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SP-420. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sideris Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSideris Pharmaceuticals

SP-420

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Transfusional Iron Overload1 trial

Thalassemia1 trial

Myelodysplastic Syndromes1 trial

Beta-Thalassemia1 trial

References

Drug Info

Quick Facts

Related News